Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
21106-1-PBS targets Collagen Type XXVI in IHC, IF/ICC, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag15382 Product name: Recombinant human EMID2 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 118-247 aa of BC110393 Sequence: GFTGSNCDEECMNCTRLSDMSERLTTLEAKVLLLEAAERPSSPDNDLPAPESTPPTWNEDFLPDAIPLAHPVPRQRRPTGPAGPPGQTGPPGPAGPPGSKGDRGQTGEKGPAGPPGLLGPPGPRGLPGEM 相同性解析による交差性が予測される生物種 |
| Full Name | EMI domain containing 2 |
| Calculated molecular weight | 441 aa, 45 kDa |
| Observed molecular weight | 45 kDa |
| GenBank accession number | BC110393 |
| Gene Symbol | EMID2 |
| Gene ID (NCBI) | 136227 |
| RRID | AB_3669359 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q96A83 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
COL26A1(Collagen alpha-1(XXVI) chain), also known as EMID2. It is expected to be located in the cytoplasm and extracellular space. COL26A1 is expressed in many tissues, especially in brain tissues, including cerebral cortex, cerebellum and basal ganglia. In the single cell type, the expression of COL26A1 is mainly concentrated in excitatory and inhibitory neurons. The protein is a new member of the collagen family. Its function has not been fully demonstrated in thyroid cancer (THCA), but it is known that collagen can promote cancer progression. COL26A1 may be involved in immune-related pathways, such as CTLA4 pathway, IL-10 signaling pathway and chemokine receptor binding chemokine. The molecular weight of COL26A1 is 45 kDa. COL26A1 is significantly up-regulated in thyroid carcinoma, and its high expression is related to poor prognosis. It is also significantly related to tumor microenvironment, which may involve immune-related pathways in the process of tumor occurrence(PMID: 38197076).